Status:
COMPLETED
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Breast Cancer
Arthralgia
Eligibility:
FEMALE
18+ years
Brief Summary
The Logribmet study is a prospective study that evaluate grip strength changes in both hands of postmenopausal women with breast cancer receiving treatment with tamoxifen or an aromatase inhibitor. Pa...
Eligibility Criteria
Inclusion
- Patients with early breast cancer who are scheduled to receive endocrine therapy with tamoxifen or any of the third-generation aromatase inhibitors, anastrozole, letrozole or exemestane.
- No major rheumatological disorders such as severe rheumatoid arthritis.
- Patients must have provided informed consent for participation in this study.
Exclusion
- Concomitant endocrine therapy for breast cancer.
- Concomitant intake of sex hormone containing drugs such as hormone replacement therapy.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT01223833
Start Date
April 1 2009
End Date
June 1 2013
Last Update
July 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Belgium, 3000